Skip to main content
$53.37 -$0.29 (-0.5%)

04:00 PM EST on 01/19/21

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Current Price $53.37 Mkt Cap $8.5B
Open $54.49 P/E Ratio 0.00
Prev. Close $53.66 Div. (Yield) $0.00 (0.0%)
Daily Range $53.15 - $54.50 Volume 684,251
52-Wk Range $30.02 - $58.72 Avg. Daily Vol. 895,787

Caps

How do you think NASDAQ:ACAD will perform against the market?

Add Stock to CAPS Watchlist

All Players

290 Outperform
72 Underperform
 

All-Star Players

46 Outperform
13 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACAD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MarkBiotech (25.04)
Submitted April 05, 2017

Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More

constructive (28.13)
Submitted March 03, 2017

This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More

Recent Community Commentary

Read the most recent pitches from players about ACAD.

Recs

0
Member Avatar swt99 (< 20) Submitted: 10/8/2020 8:43:49 PM : Outperform Start Price: $41.45 NASDAQ:ACAD Score: +18.04

I got this one cause it came highly recommended. only keep for a short time then sale. They predict that it may got high

Recs

0
Member Avatar pitbullsneedlove (91.14) Submitted: 8/15/2020 6:51:41 PM : Outperform Start Price: $39.85 NASDAQ:ACAD Score: +21.88

It’s already profitable and I see a lot of uses for its medicine.

Recs

0
Member Avatar LifeScientist (81.95) Submitted: 7/2/2020 3:08:37 PM : Outperform Start Price: $52.08 NASDAQ:ACAD Score: -18.24

The principal pipieline drug Nuplazid seeking fda approval is already market for Parkinson’s patients. Wow, my own Mom could benefit! ....we’ve been seeking a drug that would help her hallucinations w dementia. sNDA on dementia now....hope it works and is covered by insurance!

Leaderboard

Find the members with the highest scoring picks in ACAD.

Score Leader

jamrod02

jamrod02 (61.54) Score: +6,628.27

The Score Leader is the player with the highest score across all their picks in ACAD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jamrod02 61.54 12/20/2010 Outperform 5Y $0.77 +6,832.07% +203.79% +6,628.27 0 Comment
noobtery 64.19 10/28/2010 Outperform 5Y $0.83 +6,330.12% +218.56% +6,111.56 0 Comment
Hornet41 60.84 12/22/2010 Outperform 5Y $0.90 +5,829.34% +201.76% +5,627.58 0 Comment
Ruckwerts 52.28 12/1/2011 Outperform 3Y $0.93 +5,638.71% +203.48% +5,435.23 0 Comment
dsherid2 56.15 11/30/2011 Outperform 1Y $1.03 +5,082.06% +204.77% +4,877.28 0 Comment
Smog79 < 20 8/12/2010 Outperform 3W $1.04 +5,031.73% +248.63% +4,783.10 0 Comment
drmanand 63.45 7/14/2010 Outperform 1Y $1.11 +4,708.97% +246.40% +4,462.57 1 Comment
smallandmidcap 88.93 8/10/2010 Outperform 5Y $1.13 +4,623.01% +237.99% +4,385.02 0 Comment
dmkj50 21.45 10/27/2011 Outperform 5Y $1.17 +4,461.15% +195.98% +4,265.17 0 Comment
tappo3833 88.97 1/3/2011 Outperform 1Y $1.19 +4,384.87% +198.83% +4,186.04 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACAD.